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Acute variceal bleeding (AVB) is a life-threatening complication in patients with cirrhosis. Hemostatic therapy of AVB includes
early administration of vasoactive drugs that should be combined with endoscopic therapy, preferably banding ligation. However,
failure to control bleeding or early rebleed within 5 days still occurs in 15–20% of patients with AVB. In these cases, a second endo-
scopic therapy may be attempted (mild bleeding in a hemodynamically stable patient) or we can use a balloon tamponade as a
bridge to definitive derivative treatment (i.e., a transjugular intrahepatic portosystemic shunt). Esophageal balloon tamponade
provides initial control in up to 80% of AVB, but it carries a high risk of major complications, especially in cases of long duration
of tamponade (>24 h) and when tubes are inserted by inexperienced staﬀ. Preliminary reports suggest that self-expandable covered
esophageal metallic stents eﬀectively control refractory AVB (i.e., ongoing bleeding despite pharmacological and endoscopic ther-
apy ormassive bleeding precluding endoscopic therapy) with a low incidence of complications. Thus, covered self-expandingmetal
stents may represent an alternative to the Sengstaken-Blakemore balloon for the temporary control of bleeding in treatment fail-
ures. Further studies are required to determine the role of this new device in AVB.
1. Introduction
Acute variceal bleeding (AVB) is a severe complication of
portal hypertension causing 70% of all upper gastrointestinal
bleeding episodes in patients with portal hypertension [1].
Bleeding-related death, defined as any death occurring
within six weeks of hospital admission for AVB, has de-
creased from 42% to 15–20% in the last two decades [2].
Prognostic factors for death include the severity of AVB
(mainly failure to control bleeding and/or presence of early
rebleeding), the degree of hepatic dysfunction (Child class C
and/or MELD score ≥ 18 are associated with bad prognosis)
and the development of complications, such as acute renal
failure, bacterial infections, liver decompensation or of
acute-on-chronic liver failure [2, 3].
2. Treatment of Acute Variceal Bleeding
Therapy of AVB should be aimed at correcting hypovolemia,
preventing complications associated with gastrointestinal
bleeding, and achieving hemostasis. Therefore, after initial
general management including resuscitation, airway protec-
tion, and prevention of potential complications (including
administration of prophylactic antibiotics), we must proceed
to provide specific therapy and to confirm the diagnosis of
the source of bleeding by emergency endoscopy, which
should be performed within 12 hours from arrival to hos-
pital.
Primary therapy of AVB includes early administration
of vasoactive drugs (terlipressin, somatostatin, octreotide, or
vapreotide) that should be combined with endoscopic ther-
apy preferably esophageal banding ligation (EBL) once emer-
gency endoscopy confirms bleeding from varices [3].
Figure 1 shows the algorithm of the management of AVB ac-
cording to the Baveno V consensus conference.
In 10 to 20% of patients, AVB is not controlled with this
primary endoscopic and pharmacological therapy (failure to
control bleeding or early rebleeding) [4].
To reduce the incidence of treatment failure and death,
more aggressive therapies may be used in patients at high
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Figure 1: Algorithm of the current management of acute bleeding from ruptured esophageal varices. ∗Self-expandable esophageal metallic
stent may represent an alternative to balloon tamponade in this situation. ∗∗Preferably TIPS with PTFE-covered stents (from reference [2],
with permission).
risk of treatment failure. In this sense, a recent randomized
controlled trial has shown that early transjugular intrahep-
atic portosystemic shunt (TIPS) using PTFE-covered stents
within 72 hours (preferably within ≤24 hours) markedly
reduced treatment failure as well as short-term and 1-year
mortality in high-risk patients (those Child class C < 14
points or Child with active bleeding despite being vasoactive
drug therapy). Control patients received the standard ther-
apy plus rescue TIPS in case of treatment failure. The Baveno
V consensus conference recommended that “early >TIPS
should be considered in patients at high risk of treatment
failure (e.g., Child class C < 14 points or Child class B with
active bleeding) after initial endoscopic and pharmacological
therapy” [5].
3. Rescue Therapies in Acute Variceal Bleeding
Experts agree that TIPS with PTFE-coated stents is the
treatment of choice in most patients who fail medical and
endoscopic therapy [3]. However, “rescue” TIPS albeit very
eﬀective in controlling the bleeding is associated with a very
high mortality (25–60%) due to the fact that the clinical
condition of the patients deteriorates during the days in
which bleeding is not controlled. Moreover, emergency TIPS
could not always be performed, due to either lack of medical
resources on a 24-hour basis or to the actual conditions of
the patient precluding the immediate procedure. If possible
(mild bleed in a hemodynamically stable patient), a second
endoscopic therapymay be attempted. If this fails, or if bleed-
ing is severe, balloon tamponade can be used. Consensus
was reached that balloon tamponade should ONLY be used
in massive bleeding as a temporary “bridge” until definitive
treatment could be instituted (for a maximum of 24 hours,
preferably under intensive care facilities) [3].
Balloon tamponade is aimed at obtaining hemostasis by
direct compression of the bleeding varices. The type of the
balloon varies according to the site of bleeding: the Linton-
Nachlas tube in gastric fundal varices and the Sengstaken-
Blakemore tube (Figure 2) in esophageal variceal bleeding.
In experienced hands it provides initial bleeding control
rates up to 80–90% [3, 6, 7], but recurrence is observed in
about half of the patients after deflation of the balloon [7].
Major complications have been observed in over one fourth
of the patients (fatal in 5% of the cases, especially in those
of esophageal perforation), and its incidence increases with
duration of tamponade [7] and when tubes are inserted by
inexperienced staﬀ [8]. Therefore, tamponade should only
be used by skilled and experienced personnel [9] in intensive
care facilities and with special caution in patients with
respiratory failure or cardiac arrhythmias. Because of the
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Figure 2: (a) Four lumen Sengstaken-Blakemore (Minnesota) tube.
The gastric balloon is inflated with 150–200mL of air and then
pulled on the cardioesophageal junction and secured by diﬀerent
options such as a specially designed helmet (b). The esophageal
balloon is inflated with air to a pressure of 40–50mmHg. As shown,
the tube has four lumen: the gastric and esophageal balloon inflati-
on ports and the gastric and esophageal aspiration ports.
high risk of aspiration pneumonia, tamponade should be
preceded by prophylactic orotracheal intubation in comatose
or encephalopathic patients.
In this context, preliminary studies have evaluated the
use of self-expandable covered esophageal metallic stents as
an alternative to balloon tamponade for the temporary con-
trol of bleeding in treatment failures.
4. Self-Expandable Metal Stents in
the Treatment of Acute Esophageal
Variceal Bleeding
The SX-Ella Danis stent (Ella-CS, Hradec Kralove, Czech
Republic) is a removable, covered, and self-expanding metal
stent that can be deployed in the lower esophagus without
radiological or endoscopic assistance (Figure 3). The stent
has atraumatic edges and radiopaque markers at both ends
and at the midpoint to easily assess its position by a plain
chest X-ray. Retrieval loops with gold markers at both stent
ends allow the endoscopic extraction of the stent with a
specifically designed system (PEX-Ella or Extractor for SX-
Ella Stent Danis) (Figure 3).
Initial studies came from the center who developed the
technique. Hubmann and coworkers reported the results in
20 patients with massive ongoing bleeding despite previous
endoscopic treatment or balloon tamponade [10]. Interest-
ingly, the first five patients received a nonspecifically de-
signed esophageal stent (Choo stent and Ella-Boubela-Danis
stent in 2 and 3 cases, respectively). Meanwhile, a new type
of stent was specifically designed to treat bleeding esophageal
varices (the SX-Ella Danis stent), and was used in the 15
remaining patients received. This pilot study showed that
esophageal stenting for ABV was easily applicable (100%
implantation success), suﬃciently secure (except for 5 cases
of migration of the stent to the stomach requiring further
reposition), safe (no local complications were observed de-
spite the stent remaining in place for 2 to 14 days) and highly
eﬀective, achieving hemostasis in all the patients included.
The same authors presented recently an extended study, in-
cluding 39 patients with active bleeding despite previous
therapy [11]. The results were identical to those of their first
report: stent insertion resulted in immediate hemostasis in 33
of 34 patients; further therapy (either endoscopic, radiologi-
cal, or surgical) was possible in the majority of the patients;
the only adverse event observed was stent migration in 7
patients, but this was not associated with bleeding, and the
stent could be repositioned in all the cases by using the PEX-
Ella extractor. 30-day survival was 74%.
A group of British investigators published their experi-
ence in 10 patients with variceal hemorrhage with contra-
indications to TIPS insertion (due to extremely advanced
liver failure, multiorgan failure, or hepatocellular carcinoma)
or balloon tamponade (failure of balloon insertion or bal-
loon-induced esophageal tear) [12]. The SX-Ella Danis stent
insertion was successfully placed in 9 of the 10 patients, tech-
nically easy (without need for fluoroscopic control), eﬀective
(7 of 10 patients achieving hemostasis), safe (no major com-
plications were observed) and could be used as an eﬀective
bridge to definite therapies (i.e., TIPS), since being in place
for several days after achieving hemostasis allowed patient to
improve enough as to be safely treated. Overall survival at 42
days in this short series of high-risk patients was 50%.
5. Self-Expandable Metal Stents versus
Balloon Tamponade in the Treatment of
Acute Esophageal Variceal Bleeding:
Potential Indications, Limitations,
Technical Requirements, and Complications
5.1. Indications. Potential indications for esophageal stenting
not only relate to refractory variceal bleeding but also to
cover large esophageal tears [12, 13], mainly induced by the
Sengstaken-Blakemore tube, and banding or sclerotherapy-
related ulcers [14].
Since the SX-Ella Danis stent could remain in place up
to 7 days (and has been used for up to 14 days) [10–13],
this may allow the patient to fully recover from the bleeding,
unlike the Sengstaken-Blakemore balloon, that can be kept
inflated for only 24 hours [3]. Therefore, the “extra” time in
hemostasis given by the esophageal stent will permit some
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Figure 3: (a) Design of the SX-Ella Danis stent including radiopaque markers as well as the gold markers for stent removal. (b) Endoscopic
view of the esophagus with the proximal end of the stent showing the extraction loop (gold marker).
patients with relative contraindications to TIPS, such as he-
patic encephalopathy, acute respiratory failure, and so forth,
to improve enough to allow the safe placement of a TIPS or
to go to other elective therapy without further bleeding [12].
If safety is confirmed in large series, it could also be pro-
posed to use esophageal stents earlier in the course of bleed-
ing, before declaring it “refractory” to standard therapy (for
instance in high-risk patients needing to be transferred to
another center for TIPS, or for patients with comorbidities
precluding TIPS).
5.2. Limitations. Gastric varices will not be adequately
compressed by the stent whereas the gastric balloon of the
Sengstaken-Blakemore tube may have a role in some patients
(GOV1 and some cases of GOV2). Nevertheless, it should be
considered that most fundal varices (IGV1 and the majority
of GOV2) will not be correctly treated by either the SX-
Ella Danis stent or the Sengstaken-Blakemore tube. In these
cases, endoscopic obturation with bucrylate is indicated, and
tamponade with a Linton-Nachlas tube may be used in
failures as a bridge to TIPS.
In patients with massive bleeding, in whom esophageal
stent was deployed without previous diagnostic endoscopy,
the persistence of bleeding strongly raises the suspicion of
bleeding gastric varices [12]. In these cases, the insertion of a
Linton-Nachlas tube, if therapeutic endoscopy is not feasible,
should be considered.
5.3. Technical Requirements. Although both balloon tam-
ponade and esophageal stenting could be deployed at the
emergency room or the endoscopy room, the characteristics
of the patients requiring such therapies advise to admit them
to an intensive surveillance facility (intensive care unit,
bleeding unit, . . .) attended by experienced physicians and
nurses.
In this sense, it should be noted that therapy of ABV is
not only directed at achieving hemostasis, but also at pre-
venting bleeding-related complications (aspiration pneumo-
nia, bacterial infections, renal failure, hepatic encephalopa-
thy, etc.) [2, 3].
The technical requirements to insert either a Sengstaken-
Blakemore tube or an SX-Ella Danis stent are scarce. In fact,
both devices could be inserted and inflated/deployed without
radiological or endoscopic assistance. It should be taken
into account that most of the published cases of esophageal
stents to treat AVB were deployed in the lower esophagus
over an endoscopically placed guide wire [10–12] although,
in our personal experience, this has not been necessary in
patients without special esophageal conditions (hiatal hernia,
strictures, lacerations . . .).
Figure 2 shows the step-by-step diagnostic and therapeu-
tic algorithm in AVB. As shown, vasoactive therapy should
be initiated as soon as possible followed by diagnostic endos-
copy (in a hemodynamically stable patient). The initial en-
doscopy must confirm the source of bleeding, assess the
severity of AVB and risk factors for failure to control bleed-
ing, and evaluate the anatomy of the esophagus. During this
procedure, endoscopic therapy, preferably banding ligation,
must be performed. If the presence of active or massive
bleeding precludes endoscopic therapy, we can choose bet-
ween retiring the endoscope and inserting a Sengstaken-
Blakemore tube or introducing a guide wire through the
endoscope and afterwards use it to facilitate the insertion of
the SX-Ella Danis stent. Unfortunately, in some cases, the
bleeding is so as to preclude endoscopy, and we have to
proceed to emergency tamponade without the possibility of
confirming the source of bleeding, of discarding the presence
of a giant hiatal hernia or of esophageal strictures, and with-
out introducing a guide wire.
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After the placement of both the balloon or the stent, a
chest radiograph must be taken to confirm that the device is
correctly positioned.
5.4. Potential Complications. As previously mentioned, bal-
loon tamponade can be associated with severe complications
the most dreadful being esophageal perforation [7]. Usually,
perforation occurs when the gastric balloon migrates or is
initially inflated within the esophagus [15].
To avoid this often lethal complication, the SX-Ella Danis
stent has a security pressure valve that does not allow the
gastric balloon being inflated against resistance. This min-
imizes the risk of esophageal perforation in inexperienced
hands. Moreover, as some authors described [12, 13], the
covered esophageal stent achieved excellent results prevent-
ing mediastinitis and further bleeding in patients with eso-
phageal perforations induced by a previous attempt at
balloon tamponade.
Fortunately, esophageal perforation is not the most fre-
quent complication of balloon tamponade. This first position
is reserved for aspiration pneumonia. The high incidence
of this complication (47% in our unit) leads to the recom-
mendation of protecting the patient’s airway by means of
endotracheal intubation whenever a Sengstaken-Blakemore
tube is in place. Aspiration in many cases occurs during
placement of the Sengstaken-Blakemore tube in an actively
bleeding patients; in others, it is due to the fact that supra-
glottic secretions accumulate over the esophageal balloon
and enter the tracheobronchial tree despite the presence of an
esophageal aspiration port (Figure 2). Esophageal stents have
the advantages of allowing the patient to swallow food (or an
endoscope) without interfering with patient’s airway. These
advantages may result in a decreased risk of pulmonary aspi-
ration and need for endotracheal intubation, and shortening
the patient’s ICU stage.
In addition, the presence of an esophageal stent is not a
problem for maintaining oral nutrition, which is an essential
component for the recovery of the patients.
6. Conclusions
According to reported data, the experts meeting at the
Baveno V consensus conference agreed that “uncontrolled
data suggest that self-expanding covered esophageal metal
stent may be an option in refractory esophageal variceal
bleeding” [3]. It should be clarified that “refractory eso-
phageal variceal bleeding” refers to ongoing bleeding despite
pharmacological and endoscopic therapy (except in massive
bleeding precluding the latter). In these cases, the SX-Ella
Danis stent would represent an alternative to the Sengstaken-
Blakemore balloon.
Nevertheless, further studies, preferably randomized
controlled trials, are required to determine the role of cov-
ered self-expanding metal stents in acute variceal bleeding.
Abbreviations
AVB: Acute variceal bleeding
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